Supprelin, Supprelin La, Vantas (histrelin) is a protein pharmaceutical. Histrelin was first approved as Supprelin on 1991-12-24. It is used to treat precocious puberty in the USA. It is known to target gonadotropin-releasing hormone receptor. Vantas's patent is valid until 2026-06-16 (FDA).
|Trade Name||Supprelin, Supprelin La, Vantas|
|Drug Class||Prehormones or hormone-release stimulating peptides|